Anticoagulant-induced intracerebral haemorrhage (ICH): risk factors and outcomes

Evidence-based neurology checklist on anticoagulant-induced intracerebral haemorrhage (ich): risk factors and outcomes: Risk factors Hypertension The risk may be higher with Rivaroxaban than with Dabigatran Epidemiology Outcomes Related Neurochecklists

Risk factors

  • Hypertension
  • The risk may be higher with Rivaroxaban than with Dabigatran

Epidemiology

Outcomes

Related Neurochecklists

References

  1. Majeed A, Kim YK, Roberts RS, Holmstrom M, Schulman S. Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke 2010; 41:2860-2866.
  2. Toyoda K, Yasaka M, Uchiyima S, et al. Blood pressure levels and bleeding events during antithrombotic therapy: the bleeding with antithrombotic therapy (BAT) study. Stroke 2010; 41:1440-1444.
  3. Graham DJ, Reichman ME, Wernecke M, et al. Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med 2016; 176:1662-1671.
  4. Wu TY, Yassi N, Shah DG, et al. Simultaneous multiple intracerebral hemorrhages (SMICH). Stroke 2017; 48:581-586. 
  5. Boulouis G, Morotti A, Pasi M, Goldstein JN, Gurol ME, Charidimou A. Outcome of intracerebral haemorrhage related to non-vitamin K antagonists oral anticoagulants versus vitamin K antagonists: a comprehensive systematic review and meta-analysis. JNNP 2017; pii: jnnp-2017-316631 (Epub ahead of print).
  6. And 2 more. Subscribe to see the full list

Related checklists

Loading...